在骨科领域，骨折不愈合是一个令人头疼的难题。想象一下，骨折患者本应在一段时间后康复，可有些患者的骨折部位却迟迟无法愈合，需要反复治疗，这不仅让患者承受身体上的痛苦，还严重降低了他们的生活质量。据统计，近 5 - 10% 的骨折会出现延迟愈合或不愈合的情况。目前，虽然有一些治疗方法，比如物理刺激疗法、lncRNA 和 miRNA ...

The licensed technology was part of the first FDA approved trial to test mesenchymal stem cell derived exosomes in cancer patients. The company's first commercial product, ExoWELL™, is a ...

The company's first commercial product, ExoWELLTM, is a physician-directed, GMP stem cell exosome supplement for application in health and wellness. It has the potential to modulate cellular ...

While the trial focuses on stem cell transplantation, it hints at broader mechanisms—like exosome release—that could transform Parkinson's care by repairing brain damage and enhancing dopamine ...

A pioneering Phase 1 clinical trial, reported in a March 9, 2025, ScienceDaily article, is advancing stem cell therapies for Parkinson's disease. After over 30 years of research, the trial reprograms ...

PranaX Corporation ( an emerging regenerative medicine biotechnology company, today announced that it has licensed exosome technology from The University of Texas MD Anderson Cancer Center to develop ...

This new study explores the potential of strontium (Sr)-enhanced exosomes, derived from synovial mesenchymal stem cells (SMSCs), as a promising therapeutic approach for temporomandibular joint ...